Literature DB >> 25407372

Ecthyma gangrenosum and ecthyma-like lesions: review article.

M Vaiman1, T Lazarovitch, L Heller, G Lotan.   

Abstract

The generally accepted definition of ecthyma gangrenosum (EG) states that this condition is pathognomonic of Pseudomonas septicemia (Pseudomonas aeruginosa) and that it should usually be seen in immunocompromised patients, particularly those with underlying malignant disease. The cases described in the literature present a somewhat different picture. Our objective was to analyze this controversy. The review analyzes 167 cases of EG that were described in the literature from 1975 to 2014. All articles on EG cases with EG-specific tissue defect that had signs of general and/or local infection and skin necrosis were included and analyzed, whatever the etiology detected. Necrotic lesions of the skin diagnosed as EG have various microbiological etiology, can occur in immunocompetent or even healthy persons, and are not necessarily connected with septicemia. In published cases, P. aeruginosa was detected in 123 cases (73.65%); of them, there were only 72 cases (58.5%) with sepsis. Other bacterial etiology was detected in 29 cases (17.35%) and fungi were detected in 15 cases (9%). While the clinical picture of the disease and the treatment strategy remain the same, there is no need to invent two separate definitions for Pseudomonas and non-Pseudomonas cases. We suggest accepting a broader definition of EG.

Entities:  

Mesh:

Year:  2014        PMID: 25407372     DOI: 10.1007/s10096-014-2277-6

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  67 in total

1.  Ecthyma gangrenosum secondary to severe invasive infection caused by Escherichia coli.

Authors:  Joana Gomes; Catarina Vilarinho; Filipa Ventura; Ana Paula Vieira; Celeste Brito
Journal:  Int J Dermatol       Date:  2012-03       Impact factor: 2.736

2.  A case of ecthyma gangrenosum.

Authors:  R H BROUGHTON
Journal:  J R Nav Med Serv       Date:  1951

3.  Facial ulcerations in an immunocompromised patient. Ecthyma gangrenosum.

Authors:  N C Blumenthal; U R Sood; P J Aronson; K Hashimoto
Journal:  Arch Dermatol       Date:  1990-04

4.  [Skin necrosis: report of eleven cases].

Authors:  Montserrat N Molgó; Camila E Arriagada; Claudia B Salomone; Cristián K Vera; Laura F Giesen; Antonieta G Solar; Sergio B González
Journal:  Rev Med Chil       Date:  2014-01       Impact factor: 0.553

5.  Ecthyma gangrenosum in a previously healthy infant.

Authors:  Su Han Koo; Joon Ho Lee; Heakyeong Shin; Jong Im Lee
Journal:  Arch Plast Surg       Date:  2012-11-14

Review 6.  Ecthyma gangrenosum in patients with acquired immunodeficiency syndrome.

Authors:  M O Khan; M A Montecalvo; I Davis; G P Wormser
Journal:  Cutis       Date:  2000-08

7.  Ecthyma gangrenosum without bacteraemia in a leukaemic patient.

Authors:  W K Song; Y C Kim; H J Park; Y W Cinn
Journal:  Clin Exp Dermatol       Date:  2001-07       Impact factor: 3.470

8.  Pseudomonas aeruginosa cellulitis and ecthyma gangrenosum in immunocompromised children.

Authors:  J E Fergie; C C Patrick; L Lott
Journal:  Pediatr Infect Dis J       Date:  1991-07       Impact factor: 2.129

9.  Ecthyma gangrenosum without pseudomonas septicemia in a kidney transplant recipient.

Authors:  Noriaki Nakai; Hideya Takenaka; Saburo Kishimoto
Journal:  J Dermatol       Date:  2008-09       Impact factor: 4.005

10.  Solitary ecthyma gangrenosum (EG)-like lesion consequent to Candida albicans in a neonate.

Authors:  Shilpi Agarwal; Meenal Sharma; Vibhu Mehndirata
Journal:  Indian J Pediatr       Date:  2007-06       Impact factor: 5.319

View more
  33 in total

1.  Answer to March 2021 Photo Quiz.

Authors:  Hugh Adler; James Cruise; Jun Yong; Amit Patel; Magda Mikhail; Michael B J Beadsworth; Nicholas J Beeching
Journal:  J Clin Microbiol       Date:  2021-02-18       Impact factor: 5.948

2.  Impact of Type III Secretion Effectors and of Phenoxyacetamide Inhibitors of Type III Secretion on Abscess Formation in a Mouse Model of Pseudomonas aeruginosa Infection.

Authors:  Bryan J Berube; Katherine R Murphy; Matthew C Torhan; Nicholas O Bowlin; John D Williams; Terry L Bowlin; Donald T Moir; Alan R Hauser
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

3.  Ecthyma gangrenosum caused by Citrobacter freundii.

Authors:  Tyson Hawkley; David Chang; Whitney Pollard; David Ferraro
Journal:  BMJ Case Rep       Date:  2017-07-27

4.  Differential diagnosis of suspected deep tissue injury.

Authors:  Joyce M Black; Christopher T Brindle; Jeremy S Honaker
Journal:  Int Wound J       Date:  2015-06-30       Impact factor: 3.315

5.  Double atypical co-infection in ecthyma gangrenosum: a peculiar case report.

Authors:  Paulus Mario Christopher; Erna Kristiani
Journal:  Germs       Date:  2022-03-31

6.  The skin as the first sign of a rare complication of rheumatoid arthritis.

Authors:  Maria Seabra Rato; Alexandra Bernardo; Filipe Oliveira Pinheiro; Diogo Guimarães da Fonseca; Lúcia Costa
Journal:  Clin Rheumatol       Date:  2022-07-23       Impact factor: 3.650

7.  [Multiple well demarcated skin erosions and ulcers following exanthematous drug eruption after sultamicillin therapy].

Authors:  A Markovic; J C Simon; R Treudler
Journal:  Hautarzt       Date:  2018-06       Impact factor: 0.751

Review 8.  Diagnosis and management of skin and soft tissue infections in the intensive care unit: a review.

Authors:  Jason P Burnham; John P Kirby; Marin H Kollef
Journal:  Intensive Care Med       Date:  2016-10-03       Impact factor: 17.440

9.  Ecthyma gangrenosum of the scrotum: a case report.

Authors:  Wei Phin Tan; Benjamin A Sherer; Jerome Hoeksema
Journal:  Front Med       Date:  2016-03-03       Impact factor: 4.592

10.  Acute myeloid leukaemia presenting with ecthyma gangrenosum as the first manifestation: A case report.

Authors:  Yoshiro Hadano; Nao Yoshida-Sakai; Yutaka Imamura; Tomohiro Inoue; Hitoshi Koga
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.